Ligocyte Acquired By Japanese Firm

Bozeman, Montana-based biopharmaceuticals developer LigoCyte Pharmaceuticals has been acquired by Japanese firm Takeda Pharmaceutical Co., Takeda said this morning. Takeda will pay $60M for LigoCyte, giving it access to LigoCyte's norovirus vaccine, aimed at treating gastroenteritis. LigoCyte is venture backed by Forward Ventures, JAFCO, Novartis Venture Fund, Fidelity Biosciences, MedImmune Ventures, Athenian Venture partners, and MC Life Sciences Ventures.